- Home
- LOCO vs DSGN Comparison
LOCO vs DSGN Comparison
Compare LOCO & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- DSGN
- Stock Information
- Founded
- LOCO 1980
- DSGN 2017
- Country
- LOCO United States
- DSGN United States
- Employees
- LOCO N/A
- DSGN N/A
- Industry
- LOCO Restaurants
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- DSGN Health Care
- Exchange
- LOCO Nasdaq
- DSGN Nasdaq
- Market Cap
- LOCO 270.6M
- DSGN 224.8M
- IPO Year
- LOCO 2014
- DSGN 2021
- Fundamental
- Price
- LOCO $11.20
- DSGN $3.71
- Analyst Decision
- LOCO Buy
- DSGN Hold
- Analyst Count
- LOCO 3
- DSGN 1
- Target Price
- LOCO $15.50
- DSGN $4.00
- AVG Volume (30 Days)
- LOCO 397.2K
- DSGN 93.8K
- Earning Date
- LOCO 07-31-2025
- DSGN 08-04-2025
- Dividend Yield
- LOCO N/A
- DSGN N/A
- EPS Growth
- LOCO 6.54
- DSGN N/A
- EPS
- LOCO 0.86
- DSGN N/A
- Revenue
- LOCO $476,032,000.00
- DSGN N/A
- Revenue This Year
- LOCO $6.28
- DSGN N/A
- Revenue Next Year
- LOCO $1.14
- DSGN N/A
- P/E Ratio
- LOCO $13.05
- DSGN N/A
- Revenue Growth
- LOCO 1.22
- DSGN N/A
- 52 Week Low
- LOCO $8.29
- DSGN $2.60
- 52 Week High
- LOCO $14.25
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- LOCO 66.21
- DSGN 47.78
- Support Level
- LOCO $10.17
- DSGN $3.66
- Resistance Level
- LOCO $11.01
- DSGN $3.84
- Average True Range (ATR)
- LOCO 0.38
- DSGN 0.25
- MACD
- LOCO -0.01
- DSGN -0.02
- Stochastic Oscillator
- LOCO 88.14
- DSGN 18.06
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.